BACKGROUND:Few studies have reported the effect of aldosterone receptor antagonist(ARA) on myocardial remodeling after acute myocardial infarction(AMI).This study was undertaken to investigate the preventive effect of...BACKGROUND:Few studies have reported the effect of aldosterone receptor antagonist(ARA) on myocardial remodeling after acute myocardial infarction(AMI).This study was undertaken to investigate the preventive effect of ARA on myocardial remodeling after AMI.METHODS:A total of 616 patients who had been admitted into the CCU of the First Affiliated Hospital of Harbin Medical University from January 2008 to January 2010 were studied prospectively.Only 528 patients were observed completely,including 266 of the control group and 262 of the treatment group.There was no statistical difference in age,gender,medical history,admission situation,and treatment between the two groups(P>0.05).The preventive effects of spironolactone on cardiac remodeling,left ventricular function,renal function and blood levels of potassium were evaluated by echocardiography,serum potassium and serum creatinine at one-month and one-year follow-up.RESULTS:The echocardiography indicators such as LVESD,LVEDD,LVEF,LAD-ML and LADSI were significantly improved in the treatment group compared with the control group at one year(P<0.05).In the treatment group,LVESD,LVEDD,LVPWT,LVEF,LAD-ML and LAD-SI were more significantly improved at one year than one month(P<0.05,P=0.007 to LVEF),and in the control group LVEF was more significantly improved at one year than one month(P=0.0277).There were no significant differences in serum potassium and serum creatinine levels between the two groups.CONCLUSION:On the basis of conventional treatment,the early combination of low-dose spironolactone(20 mg/d) could inhibit cardiac remodeling at late stage and prevent heart fadure.展开更多
Co-amorphous solid dispersion(C-ASD)systems have attracted great attention to improve the solubility of poorly soluble drugs,but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge ...Co-amorphous solid dispersion(C-ASD)systems have attracted great attention to improve the solubility of poorly soluble drugs,but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge challenge.Herein,C-ASD system of two clinical combined used drugs(lacidipine(LCDP)and spironolactone(SPL))as stabilizers to each other,was prepared by solvent evaporation method.The effects of variation in molar ratio of LCDP and SPL(3:1,1:1,1:3,1:6,and 1:9)on the drug release characteristics were explored.Polarized light microscopy(PLM),powder X-ray diffraction(PXRD),differential scanning calorimetry(DSC)and thermogravimetric analysis(TGA)were employed to evaluate the solid states.Prepared C-ASDs were further studied for their stability under the high humidity(RH 92.5%).Further analysis of C-ASDs via Fourier-transform infrared spectroscopy(FTIR)and Raman spectroscopy confirmed that hydrogen bond interactions between the two drugs played a significant role in maintaining the stability of the C-ASDs systems.Moreover,molecular dynamic(MD)simulations provided a clear insight into the stability mechanism at the molecular level.This study demonstrated the novel drug-drug C-ASDs systems is a promising formulation strategy for improved dissolution rate and enhanced physical stability of poorly soluble drugs.展开更多
AIM:To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy(CSCR).METHODS: Totally 60 patients(60 eyes) with a history of acute ...AIM:To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy(CSCR).METHODS: Totally 60 patients(60 eyes) with a history of acute CSCR were randomed into two groups: group A with combination of fenofibrate(200 mg) and spironolactone(100 mg),and group B with only fenofibrate(200 mg).They were taken half an hour before meals and once per day for 8wk.The changes of the visual acuity,subjective symptom,ocular surface disease index(OSDI),the tear film and optical coherence tomography were observed at 2,4,6,and 8wk before and after treatment.RESULTS: The best corrected visual acuity(BCVA,log MAR) was improved to 0.22 and 0.27 after treatment from baseline of 0.35 and 0.36 in groups A and B(P <0.05),respectively.After 8wk treatment,the central subfield thickness(CST),and subretinal fluid volumn(SFV) decreased significantly to 49.5% and 78.8% in group A,37.0% and 57.2% in group B.There were significant differences of CST and SFV in both groups(all P <0.05).CONCLUSION:Fenofibratecombinedwithspironolactone may have more clinical efficacy in the treatment of CSCR than fenofibrate only.展开更多
Background: CHF (Congestive Heart Failure) is one of the most important causes of mortality and morbidity in the world. Diuretics such as spironolactone can decrease pulmonary congestion and reduce the amount of fibro...Background: CHF (Congestive Heart Failure) is one of the most important causes of mortality and morbidity in the world. Diuretics such as spironolactone can decrease pulmonary congestion and reduce the amount of fibrosis in CHF patients. The goal was to assess whether spironolactone can decrease air way resistance and can we follow up the effect of diuretic therapy in patients of heart failure quantitatively by means of impulse oscillometry. Methods: It was clinical trial which performed in Ahvaz teaching hospital. 24 patients with congestive heart failure (CHF) which was classified as functional class II-IV and had EF Result: The age of patient was 61 ± 10 and the age of control was 57 ± 7 years old. The data of oscillometry before and after spironolactone were X5 (−0.14 ± 0.05 vs −0.14 ± 0.05, P: 0.93), R5 (0.39 ± 0.21 vs 0.39 ± 0.15, P: 0.35), X20 (−0.04 ± 0.06 vs −0.06 ± 0.06, P: 0.37), R20 (0.04 ± 0.03 vs 0.06 ± 0.06, P: 0.37), Zrs (0.39 ± 0.21 vs 0.39 ± 0.15, P: 0.35). Conclusion: There was a trend toward reduction of peripheral airway resistances in CHF patients than controls with use of 1 month of spironolactone. Although there was not significant change in the number of X5, R5, X20, R20 occurred the trend toward reduction of number triggers the point that oscillometry can be used for quantitative follow up of CHF patients.展开更多
Objective:To evaluate the application effect of telmisartan combined with spironolactone after catheter ablation of patients with paroxysmal atrial fibrillation.Methods:80 cases of patients with paroxysmal atrial fibr...Objective:To evaluate the application effect of telmisartan combined with spironolactone after catheter ablation of patients with paroxysmal atrial fibrillation.Methods:80 cases of patients with paroxysmal atrial fibrillation who received radiofrequency catheter ablation treatment from March 2013 to March 2016 in our hospital were randomly selected,these patients were divided into two groups according to the treatment methods,namely,the telmisartan with Spironolactone treatment group(combined treatment group,n=40)and the conventional therapy group(n=40).The hs-CRP,NT-proBNP,LAD and recurrence of the two groups were analyzed.Results:The hs-CRP,NT-proBNP levels after 3 months of the combined treatment group were significantly lower(P<0.05),the recurrence rate 10.0%(4/40)was significantly lower than the conventional therapy group 27.5%(11/40)(P<0.05),the time to recurrence was significantly longer than the conventional therapy group(P<0.05).Conclusion:The application effects of telmisartan combined with spironolactone after catheter ablation in the treatment of patients with paroxysmal atrial fibrillation are better than conventional therapy.展开更多
Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Re...Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Result: The use of spironolactone and dapagliflozin was shown to be effective in improving the clinical outcome and reducing CV hospitalization rate and CV mortality in patients with heart failure preserved left ventricular ejection fraction (HFpEF). This is the case presentation of one patient with HFpEF with diastolic dysfunction grade 3, obesity grade 3, Type 2 Diabetes, and Atrial Fibrillation (permanent). In the case of a 76-year-old female after previous ineffective treatment, the initiation of Spironolactone and Dapagliflozin led to a rapid and marked improvement in the clinical conditions. Diastolic dysfunction was improved from stage III to stage I. Moreover, the initiation of spironolactone and dapagliflozin therapy avoided a referral for surgical intervention and interrupted a long series of hospitalizations for acute HF and prevented CV death. Conclusion: Based on our experience, we conclude that the treatment with spironolactone and dapagliflozin allows for better treatment optimization with a positive impact on the control of clinical outcomes and preventing CV death and CV hospitalization in HFpEF and related comorbidities in the African population, which is underrepresented in most of the trials.展开更多
AIM: To study the hemodynamic effects of spironolactone with propranolol vs propranolol alone in the secondary prophylaxis of variceal bleeding. METHODS: Thirty-five cirrhotics with variceal bleeding randomly received...AIM: To study the hemodynamic effects of spironolactone with propranolol vs propranolol alone in the secondary prophylaxis of variceal bleeding. METHODS: Thirty-five cirrhotics with variceal bleeding randomly received propranolol (n = 17: Group A) or spironolactone plus propranolol (n = 18: Group B). Hemodynamic assessment was performed at baseline and on the eighth day. RESULTS: Spironolactone with propranolol caused a greater reduction in the hepatic venous pressure gradient than propranolol alone (26.94% vs 10.2%; P < 0.01). Fourteen out of eighteen patients on the combination treatment had a reduction in hepatic venous pressure gradient to ≤ 12 mmHg or a 20% reduction from baseline in contrast to only six out of seventeen (6/17) on propranolol alone (P < 0.05). CONCLUSION: Spironolactone with propranolol results in a better response with a greater reduction in hepatic venous pressure gradient in the secondary prophylaxis of variceal bleeding. A greater number of patients may be protected by this combination therapy than by propranolol alone. Hence, this combination may be recommended for secondary prophylaxis in patients with variceal bleeding.展开更多
The redox behavior of spironolactone(SP) drug in Britton-Robinson(BR) buffer of pH 2-11 was investigated by differential pulse cathodic stripping voltammetry(DPCSV) and cyclic voltammetry(CV) at hanging mercury droppi...The redox behavior of spironolactone(SP) drug in Britton-Robinson(BR) buffer of pH 2-11 was investigated by differential pulse cathodic stripping voltammetry(DPCSV) and cyclic voltammetry(CV) at hanging mercury dropping electrode(HMDE).At pH 9-10.5,the DPCSV of SP drug showed two cathodic peaks at1.15 and1.38 V at the HMDE vs.Ag/AgCl reference electrode.In the CV,at pH 9-10,the dependence of the cathodic peak current,Ip,c and peak potential,Ep,c of the second peak(Ep,c2) on the scan rate(n) and on the depolizer(SP) concentrations was typical of an electrode coupled(EC) chemical reaction type mechanism.The plot of Ip,cat 1.380 V of the DPCSV vs.SP concentration at pH 9 was linear over the concentration range of 1.2×1010-9.6×107 M.The lower limit of detection(LLOD) and limit of quantification(LOQ) of the drug were 1.1×1011 and 4.14×1011 M,respectively.The method was successfully applied for the analysis of SP residues in industrial wastewater,in pure form(98.273.1%) and in drug formulations e.g.Aldactones tablet(98.3572.9%).The method was validated by comparison with HPLC and the official data methods.展开更多
Objective: To observe the clinical efficacy of Chibixiao Recipe (赤鼻消方, CBX) in combination with minocycline and spironolactone in treating rosacea in females. Methods: Sixty-eight women with rosacea were randomly ...Objective: To observe the clinical efficacy of Chibixiao Recipe (赤鼻消方, CBX) in combination with minocycline and spironolactone in treating rosacea in females. Methods: Sixty-eight women with rosacea were randomly assigned to the treated group (48 cases) and the control group (20 cases), both of which were treated with minocycline and spironolactone taken orally, but to the treated group, the Chinese herbal recipe, CBX was given additionally. Besides, cryotherapy with liquid nitrogen was applied to those with apparent capillary dilatation. The therapeutic course for both groups was 8 weeks. The levels of serum testosterone before and after treatment were determined by radioimmunoassay (RIA), and a 4-month follow-up was conducted. Results: In the treated group the cure-markedly effective rate was 87.5% and the recurrent rate was 6.5%, while in the control group, they were 45.0% and 41.2% respectively. Comparisons in the indexes between the two groups all showed significant difference (both P< 0.01), with the cure-markedly effective rate higher, and the recurrent rate lower in the treated group. The serum level of testosterone got lowered in both groups ( P< 0.05 and P< 0.01), but the lowering in the treated group was more significant, showing significance when compared with that in the control group ( P< 0.01). Conclusion: CBX in combination with Western medicine has effect in treating rosacea superior to that of Western medicine alone, and could effectively reduce recurrent rate and the serum level of testosterone.展开更多
目的探讨螺内酯联合缬沙坦在早期糖尿病肾病治疗中的价值。方法120例早期糖尿病肾病患者,按随机数字表法分为对照组和研究组,每组60例。对照组选择缬沙坦治疗,研究组选择螺内酯联合缬沙坦治疗。对比两组患者治疗效果、血糖指标[糖化血...目的探讨螺内酯联合缬沙坦在早期糖尿病肾病治疗中的价值。方法120例早期糖尿病肾病患者,按随机数字表法分为对照组和研究组,每组60例。对照组选择缬沙坦治疗,研究组选择螺内酯联合缬沙坦治疗。对比两组患者治疗效果、血糖指标[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PBG)及空腹血糖(FBG)]、肾功能指标[血清肌酐(SCr)、24 h尿蛋白定量、血清尿素氮(BUN)]、炎性因子[白细胞介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)]、血脂指标[总胆固醇(TC)、甘油三酯(TG)以及低密度脂蛋白胆固醇(LDL-C)]、血液流变学指标、生活质量。结果研究组患者治疗总有效率为95.0%,高于对照组的83.3%,差异具有统计学意义(P<0.05)。治疗后,研究组患者HbA1c、2 h PBG、FBG水平分别为(7.3±0.5)%、(7.9±0.5)mmol/L、(6.9±0.3)mmol/L,均低于对照组的(8.6±0.7)%、(9.3±0.8)mmol/L、(7.7±0.5)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者SCr、24 h尿蛋白定量、BUN水平分别为(228.1±23.2)μmol/L、(1.01±0.12)g/24 h、(11.76±2.64)mmol/L,均低于对照组的(308.3±24.1)μmol/L、(1.33±0.15)g/24 h、(15.17±2.36)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者IL-6、PCT、CRP、TC、TG、LDL-C水平分别为(28.5±6.6)pg/ml、(0.2±0.1)ng/L、(9.3±2.4)mg/L、(5.13±1.20)mmol/L、(1.25±0.70)mmol/L、(2.59±0.60)mmol/L,均低于对照组的(34.5±8.2)pg/ml、(0.8±0.1)ng/L、(13.6±3.2)mg/L、(5.79±1.30)mmol/L、(1.82±0.80)mmol/L、(3.25±0.60)mmol/L,差异具有统计学意义(P<0.05)。治疗后,两组患者全血高切粘度、全血低切粘度、血浆粘度、血细胞比容、纤维蛋白原水平均低于本组治疗前,且研究组患者低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者情感职能、躯体疼痛、精神健康、生理职能、社会功能、生理功能、活力、总体健康评分均高于本组治疗前,且研究组患者高于对照组,差异具有统计学意义(P<0.05)。结论螺内酯联合缬沙坦治疗早期糖尿病肾病效果显著,可以有效改善机体的血糖水平、肾功能指标、血脂水平,使炎症水平进一步降低,调节血液流变学指标,帮助患者快速康复,从而提高生活质量,值得推广。展开更多
基金supported by a grant from Science and Technology Planning Project of Heilongjiang Province,China(GB08C402-01)
文摘BACKGROUND:Few studies have reported the effect of aldosterone receptor antagonist(ARA) on myocardial remodeling after acute myocardial infarction(AMI).This study was undertaken to investigate the preventive effect of ARA on myocardial remodeling after AMI.METHODS:A total of 616 patients who had been admitted into the CCU of the First Affiliated Hospital of Harbin Medical University from January 2008 to January 2010 were studied prospectively.Only 528 patients were observed completely,including 266 of the control group and 262 of the treatment group.There was no statistical difference in age,gender,medical history,admission situation,and treatment between the two groups(P>0.05).The preventive effects of spironolactone on cardiac remodeling,left ventricular function,renal function and blood levels of potassium were evaluated by echocardiography,serum potassium and serum creatinine at one-month and one-year follow-up.RESULTS:The echocardiography indicators such as LVESD,LVEDD,LVEF,LAD-ML and LADSI were significantly improved in the treatment group compared with the control group at one year(P<0.05).In the treatment group,LVESD,LVEDD,LVPWT,LVEF,LAD-ML and LAD-SI were more significantly improved at one year than one month(P<0.05,P=0.007 to LVEF),and in the control group LVEF was more significantly improved at one year than one month(P=0.0277).There were no significant differences in serum potassium and serum creatinine levels between the two groups.CONCLUSION:On the basis of conventional treatment,the early combination of low-dose spironolactone(20 mg/d) could inhibit cardiac remodeling at late stage and prevent heart fadure.
基金financially supported by the National Basic Research Program of China(973 Program,No.2015CB932100)the National Nature Science Foundation of China(No.81473164)Key projects of Liaoning Province Department of Education(No.2017LZD03)。
文摘Co-amorphous solid dispersion(C-ASD)systems have attracted great attention to improve the solubility of poorly soluble drugs,but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge challenge.Herein,C-ASD system of two clinical combined used drugs(lacidipine(LCDP)and spironolactone(SPL))as stabilizers to each other,was prepared by solvent evaporation method.The effects of variation in molar ratio of LCDP and SPL(3:1,1:1,1:3,1:6,and 1:9)on the drug release characteristics were explored.Polarized light microscopy(PLM),powder X-ray diffraction(PXRD),differential scanning calorimetry(DSC)and thermogravimetric analysis(TGA)were employed to evaluate the solid states.Prepared C-ASDs were further studied for their stability under the high humidity(RH 92.5%).Further analysis of C-ASDs via Fourier-transform infrared spectroscopy(FTIR)and Raman spectroscopy confirmed that hydrogen bond interactions between the two drugs played a significant role in maintaining the stability of the C-ASDs systems.Moreover,molecular dynamic(MD)simulations provided a clear insight into the stability mechanism at the molecular level.This study demonstrated the novel drug-drug C-ASDs systems is a promising formulation strategy for improved dissolution rate and enhanced physical stability of poorly soluble drugs.
基金Supported by National Natural Science Foundation of China(No.81160118No.81400372+4 种基金No.81660158)Jiangxi Province Voyage Project(No.2014022)Youth Science Foundation of Jiangxi Province(No.20151BAB215016)Technology and Science Foundation of Jiangxi Province(No.20151BBG70223)Health Development Planning Commission Science Foundation of Jiangxi Province(No.20155154)
文摘AIM:To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy(CSCR).METHODS: Totally 60 patients(60 eyes) with a history of acute CSCR were randomed into two groups: group A with combination of fenofibrate(200 mg) and spironolactone(100 mg),and group B with only fenofibrate(200 mg).They were taken half an hour before meals and once per day for 8wk.The changes of the visual acuity,subjective symptom,ocular surface disease index(OSDI),the tear film and optical coherence tomography were observed at 2,4,6,and 8wk before and after treatment.RESULTS: The best corrected visual acuity(BCVA,log MAR) was improved to 0.22 and 0.27 after treatment from baseline of 0.35 and 0.36 in groups A and B(P <0.05),respectively.After 8wk treatment,the central subfield thickness(CST),and subretinal fluid volumn(SFV) decreased significantly to 49.5% and 78.8% in group A,37.0% and 57.2% in group B.There were significant differences of CST and SFV in both groups(all P <0.05).CONCLUSION:Fenofibratecombinedwithspironolactone may have more clinical efficacy in the treatment of CSCR than fenofibrate only.
文摘Background: CHF (Congestive Heart Failure) is one of the most important causes of mortality and morbidity in the world. Diuretics such as spironolactone can decrease pulmonary congestion and reduce the amount of fibrosis in CHF patients. The goal was to assess whether spironolactone can decrease air way resistance and can we follow up the effect of diuretic therapy in patients of heart failure quantitatively by means of impulse oscillometry. Methods: It was clinical trial which performed in Ahvaz teaching hospital. 24 patients with congestive heart failure (CHF) which was classified as functional class II-IV and had EF Result: The age of patient was 61 ± 10 and the age of control was 57 ± 7 years old. The data of oscillometry before and after spironolactone were X5 (−0.14 ± 0.05 vs −0.14 ± 0.05, P: 0.93), R5 (0.39 ± 0.21 vs 0.39 ± 0.15, P: 0.35), X20 (−0.04 ± 0.06 vs −0.06 ± 0.06, P: 0.37), R20 (0.04 ± 0.03 vs 0.06 ± 0.06, P: 0.37), Zrs (0.39 ± 0.21 vs 0.39 ± 0.15, P: 0.35). Conclusion: There was a trend toward reduction of peripheral airway resistances in CHF patients than controls with use of 1 month of spironolactone. Although there was not significant change in the number of X5, R5, X20, R20 occurred the trend toward reduction of number triggers the point that oscillometry can be used for quantitative follow up of CHF patients.
基金Observational study on effect of transcatheter radiofrequency ablation on patients with different types of atrial fibrillation(Project No.:172302089)。
文摘Objective:To evaluate the application effect of telmisartan combined with spironolactone after catheter ablation of patients with paroxysmal atrial fibrillation.Methods:80 cases of patients with paroxysmal atrial fibrillation who received radiofrequency catheter ablation treatment from March 2013 to March 2016 in our hospital were randomly selected,these patients were divided into two groups according to the treatment methods,namely,the telmisartan with Spironolactone treatment group(combined treatment group,n=40)and the conventional therapy group(n=40).The hs-CRP,NT-proBNP,LAD and recurrence of the two groups were analyzed.Results:The hs-CRP,NT-proBNP levels after 3 months of the combined treatment group were significantly lower(P<0.05),the recurrence rate 10.0%(4/40)was significantly lower than the conventional therapy group 27.5%(11/40)(P<0.05),the time to recurrence was significantly longer than the conventional therapy group(P<0.05).Conclusion:The application effects of telmisartan combined with spironolactone after catheter ablation in the treatment of patients with paroxysmal atrial fibrillation are better than conventional therapy.
文摘Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Result: The use of spironolactone and dapagliflozin was shown to be effective in improving the clinical outcome and reducing CV hospitalization rate and CV mortality in patients with heart failure preserved left ventricular ejection fraction (HFpEF). This is the case presentation of one patient with HFpEF with diastolic dysfunction grade 3, obesity grade 3, Type 2 Diabetes, and Atrial Fibrillation (permanent). In the case of a 76-year-old female after previous ineffective treatment, the initiation of Spironolactone and Dapagliflozin led to a rapid and marked improvement in the clinical conditions. Diastolic dysfunction was improved from stage III to stage I. Moreover, the initiation of spironolactone and dapagliflozin therapy avoided a referral for surgical intervention and interrupted a long series of hospitalizations for acute HF and prevented CV death. Conclusion: Based on our experience, we conclude that the treatment with spironolactone and dapagliflozin allows for better treatment optimization with a positive impact on the control of clinical outcomes and preventing CV death and CV hospitalization in HFpEF and related comorbidities in the African population, which is underrepresented in most of the trials.
文摘AIM: To study the hemodynamic effects of spironolactone with propranolol vs propranolol alone in the secondary prophylaxis of variceal bleeding. METHODS: Thirty-five cirrhotics with variceal bleeding randomly received propranolol (n = 17: Group A) or spironolactone plus propranolol (n = 18: Group B). Hemodynamic assessment was performed at baseline and on the eighth day. RESULTS: Spironolactone with propranolol caused a greater reduction in the hepatic venous pressure gradient than propranolol alone (26.94% vs 10.2%; P < 0.01). Fourteen out of eighteen patients on the combination treatment had a reduction in hepatic venous pressure gradient to ≤ 12 mmHg or a 20% reduction from baseline in contrast to only six out of seventeen (6/17) on propranolol alone (P < 0.05). CONCLUSION: Spironolactone with propranolol results in a better response with a greater reduction in hepatic venous pressure gradient in the secondary prophylaxis of variceal bleeding. A greater number of patients may be protected by this combination therapy than by propranolol alone. Hence, this combination may be recommended for secondary prophylaxis in patients with variceal bleeding.
基金funded by the Deanship of Scientific Research (DSR),King Abdulaziz University under grant number 172/428
文摘The redox behavior of spironolactone(SP) drug in Britton-Robinson(BR) buffer of pH 2-11 was investigated by differential pulse cathodic stripping voltammetry(DPCSV) and cyclic voltammetry(CV) at hanging mercury dropping electrode(HMDE).At pH 9-10.5,the DPCSV of SP drug showed two cathodic peaks at1.15 and1.38 V at the HMDE vs.Ag/AgCl reference electrode.In the CV,at pH 9-10,the dependence of the cathodic peak current,Ip,c and peak potential,Ep,c of the second peak(Ep,c2) on the scan rate(n) and on the depolizer(SP) concentrations was typical of an electrode coupled(EC) chemical reaction type mechanism.The plot of Ip,cat 1.380 V of the DPCSV vs.SP concentration at pH 9 was linear over the concentration range of 1.2×1010-9.6×107 M.The lower limit of detection(LLOD) and limit of quantification(LOQ) of the drug were 1.1×1011 and 4.14×1011 M,respectively.The method was successfully applied for the analysis of SP residues in industrial wastewater,in pure form(98.273.1%) and in drug formulations e.g.Aldactones tablet(98.3572.9%).The method was validated by comparison with HPLC and the official data methods.
文摘Objective: To observe the clinical efficacy of Chibixiao Recipe (赤鼻消方, CBX) in combination with minocycline and spironolactone in treating rosacea in females. Methods: Sixty-eight women with rosacea were randomly assigned to the treated group (48 cases) and the control group (20 cases), both of which were treated with minocycline and spironolactone taken orally, but to the treated group, the Chinese herbal recipe, CBX was given additionally. Besides, cryotherapy with liquid nitrogen was applied to those with apparent capillary dilatation. The therapeutic course for both groups was 8 weeks. The levels of serum testosterone before and after treatment were determined by radioimmunoassay (RIA), and a 4-month follow-up was conducted. Results: In the treated group the cure-markedly effective rate was 87.5% and the recurrent rate was 6.5%, while in the control group, they were 45.0% and 41.2% respectively. Comparisons in the indexes between the two groups all showed significant difference (both P< 0.01), with the cure-markedly effective rate higher, and the recurrent rate lower in the treated group. The serum level of testosterone got lowered in both groups ( P< 0.05 and P< 0.01), but the lowering in the treated group was more significant, showing significance when compared with that in the control group ( P< 0.01). Conclusion: CBX in combination with Western medicine has effect in treating rosacea superior to that of Western medicine alone, and could effectively reduce recurrent rate and the serum level of testosterone.
文摘目的探讨螺内酯联合缬沙坦在早期糖尿病肾病治疗中的价值。方法120例早期糖尿病肾病患者,按随机数字表法分为对照组和研究组,每组60例。对照组选择缬沙坦治疗,研究组选择螺内酯联合缬沙坦治疗。对比两组患者治疗效果、血糖指标[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PBG)及空腹血糖(FBG)]、肾功能指标[血清肌酐(SCr)、24 h尿蛋白定量、血清尿素氮(BUN)]、炎性因子[白细胞介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)]、血脂指标[总胆固醇(TC)、甘油三酯(TG)以及低密度脂蛋白胆固醇(LDL-C)]、血液流变学指标、生活质量。结果研究组患者治疗总有效率为95.0%,高于对照组的83.3%,差异具有统计学意义(P<0.05)。治疗后,研究组患者HbA1c、2 h PBG、FBG水平分别为(7.3±0.5)%、(7.9±0.5)mmol/L、(6.9±0.3)mmol/L,均低于对照组的(8.6±0.7)%、(9.3±0.8)mmol/L、(7.7±0.5)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者SCr、24 h尿蛋白定量、BUN水平分别为(228.1±23.2)μmol/L、(1.01±0.12)g/24 h、(11.76±2.64)mmol/L,均低于对照组的(308.3±24.1)μmol/L、(1.33±0.15)g/24 h、(15.17±2.36)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者IL-6、PCT、CRP、TC、TG、LDL-C水平分别为(28.5±6.6)pg/ml、(0.2±0.1)ng/L、(9.3±2.4)mg/L、(5.13±1.20)mmol/L、(1.25±0.70)mmol/L、(2.59±0.60)mmol/L,均低于对照组的(34.5±8.2)pg/ml、(0.8±0.1)ng/L、(13.6±3.2)mg/L、(5.79±1.30)mmol/L、(1.82±0.80)mmol/L、(3.25±0.60)mmol/L,差异具有统计学意义(P<0.05)。治疗后,两组患者全血高切粘度、全血低切粘度、血浆粘度、血细胞比容、纤维蛋白原水平均低于本组治疗前,且研究组患者低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者情感职能、躯体疼痛、精神健康、生理职能、社会功能、生理功能、活力、总体健康评分均高于本组治疗前,且研究组患者高于对照组,差异具有统计学意义(P<0.05)。结论螺内酯联合缬沙坦治疗早期糖尿病肾病效果显著,可以有效改善机体的血糖水平、肾功能指标、血脂水平,使炎症水平进一步降低,调节血液流变学指标,帮助患者快速康复,从而提高生活质量,值得推广。
